Assessing effectiveness of aripiprazole lauroxil vs placebo for the treatment of schizophrenia using number needed to treat and number needed to harm
Leslie Citrome,1 Yangchun Du,2 Peter J Weiden3 1Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY, USA; 2Biostatistics, Alkermes, Inc., Waltham, MA, USA; 3Medical Affairs, Alkermes, Inc., Waltham, MA, USACorrespondence: Leslie Citrome 11 Medical Park Drive, Suite 106, Pomona...
Guardado en:
Autores principales: | Citrome L, Du Y, Weiden PJ |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c700ac7139d84a2abc3c65c982a94abc |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Long-acting formulations delivering aripiprazole: beyond single-value characterizations of steady-state pharmacokinetics
por: McConnell SA, et al.
Publicado: (2017) -
Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia
por: Chih-Sung Liang, et al.
Publicado: (2021) -
Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate
por: Such P, et al.
Publicado: (2021) -
Symptomatic stability with aripiprazole once-monthly: efficacy analyses from acute and long-term studies
por: Madera JJ, et al.
Publicado: (2019) -
Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life
por: Cuomo I, et al.
Publicado: (2018)